Faeth Therapeutics Announces Trial Collaboration and Supply Agreement With Roche
The companies will evaluate PIKTOR with a selective estrogen receptor degrader in HR+/HER2- advanced breast cancer.
Story updates
12:00:33 PM UTC
SquawkNews
Faeth will sponsor and conduct a Phase 1b/2 study evaluating PIKTOR, its investigational all-oral co
12:00:49 PM UTC
SquawkNews
Faeth will sponsor and conduct a Phase 1b/2 study evaluating PIKTOR with Roche's investigational giredestrant in HR+/HER2- advanced breast cancer; Roche will supply giredestrant. Interim data is anticipated in 2027.Material DetailsContext by AI AnalystThis is an early-stage clinical development upd…
12:03:36 PM UTC
SquawkNews
Faeth Therapeutics Partners With Roche on Phase 1b/2 Trial of PIKTOR Combination in Advanced Breast
12:03:45 PM UTC
SquawkNews
FAETH THERAPEUTICS - RETAINS ALL RIGHTS TO PIKTOR; ROCHE TO SUPPLY GIREDESTRANT FOR STUDY